Diarrhoea of unknown cause: medical treatment in a stepwise manner

References

• Schiller LR, Pardi DS, Sellin JH. Chronic diarrhea: diagnosis and management. Clin Gastroenterol Hepatol. 2017;15(2):182–193 e3. doi: 10.1016/j.cgh.2016.07.028.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Sellin JH, Barrett KE. Pathophysiology, evaluation, and management of chronic watery diarrhea. Gastroenterology. 2017;152(3):515–532 e2. doi: 10.1053/j.gastro.2016.10.014.
   PubMed Web of Science ®Google Scholar
• Nordin E, Hellström PM, Brunius C, et al. Modest conformity between self-reporting of bristol stool form and fecal consistency measured by stool water content in irritable bowel syndrome and a FODMAP and gluten trial. Am J Gastroenterol. 2022;117(10):1668–1674. doi: 10.14309/ajg.0000000000001942.
   PubMed Web of Science ®Google Scholar
• O’Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ. 1990;300(6722):439–440. doi: 10.1136/bmj.300.6722.439.
   PubMed Web of Science ®Google Scholar
• Nagarajan N, Morden A, Bischof D, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015;27(9):1002–1010. doi: 10.1097/MEG.0000000000000425.
   PubMed Web of Science ®Google Scholar
• McRorie JW.Jr. Evidence-based approach to fiber supplements and clinically meaningful health benefits, part 2: what to look for and how to recommend an effective fiber therapy. Nutr Today. 2015;50(2):90–97. doi: 10.1097/NT.0000000000000089.
   PubMedGoogle Scholar
• Petruccelli BP, Murphy GS, Sanchez JL, et al. Treatment of traveler’s diarrhea with ciprofloxacin and loperamide. J Infect Dis. 1992;165(3):557–560. doi: 10.1093/infdis/165.3.557.
   PubMed Web of Science ®Google Scholar
• Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med. 1993;118(8):582–586. doi: 10.7326/0003-4819-118-8-199304150-00002.
   PubMed Web of Science ®Google Scholar
• Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):e447-60–e460. doi: 10.1016/S1470-2045(14)70006-3.
   PubMed Web of Science ®Google Scholar
• Wu PE, Juurlink DN. Loperamide cardiac toxicity: pathophysiology, presentation, and management. Can J Cardiol. 2022;38(9):1378–1383. doi: 10.1016/j.cjca.2022.04.005.
   PubMed Web of Science ®Google Scholar
• Doser K, Meyer B, Nitsche V, et al. Bioequivalence evaluation of two different oral formulations of loperamide (diarex lactab vs imodium capsules). Int J Clin Pharmacol Ther. 1995;33(8):431–436.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 2015;9(3):332–339. doi: 10.5009/gnl14397.
   PubMed Web of Science ®Google Scholar
• Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63. doi: 10.1177/1758834009355164.
   PubMedGoogle Scholar
• Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008;6(5):545–555. doi: 10.1016/j.cgh.2007.12.015.
   PubMed Web of Science ®Google Scholar
• Spiller RC. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. Curr Opin Pharmacol. 2011;11(1):68–74. doi: 10.1016/j.coph.2011.02.005.
   PubMed Web of Science ®Google Scholar
• Steadman CJ, Talley NJ, Phillips SF, et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc. 1992;67(8):732–738. doi: 10.1016/s0025-6196(12)60797-6.
   PubMed Web of Science ®Google Scholar
• Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014;2014:141737–141736. doi: 10.1155/2014/141737.
   PubMed Web of Science ®Google Scholar
• Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014;2(1):17–21. doi: 10.1038/ajgsup.2014.5.
   PubMedGoogle Scholar
• Ling GS, Paul D, Simantov R, et al. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci. 1989;45(18):1627–1636. doi: 10.1016/0024-3205(89)90272-5.
   PubMed Web of Science ®Google Scholar
• Findlay JW, Butz RF, Welch RM. Codeine kinetics as determined by radioimmunoassay. Clin Pharmacol Ther. 1977;22(4):439–446. doi: 10.1002/cpt1977224439.
   PubMed Web of Science ®Google Scholar
• Schiller LR, Davis GR, Santa Ana CA, et al. Studies of the mechanism of the antidiarrheal effect of codeine. J Clin Invest. 1982;70(5):999–1008. doi: 10.1172/jci110711.
   PubMed Web of Science ®Google Scholar
• O’Brien JD, Thompson DG, McIntyre A, et al. Effect of codeine and loperamide on upper intestinal transit and absorption in normal subjects and patients with postvagotomy diarrhoea. Gut. 1988;29(3):312–318. doi: 10.1136/gut.29.3.312.
   PubMed Web of Science ®Google Scholar
• Högenauer C, Aichbichler B, Santa Ana C, et al. Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo. Aliment Pharmacol Ther. 2002;16(4):769–777. doi: 10.1046/j.1365-2036.2002.01228.x.
   PubMed Web of Science ®Google Scholar
• Cello JP, Grendell JH, Basuk P, et al. Effect of octreotide on refractory AIDS-associated diarrhea. A prospective, multicenter clinical trial. Ann Intern Med. 1991;115(9):705–710. doi: 10.7326/0003-4819-115-9-705.
   PubMed Web of Science ®Google Scholar
• Zidan J, Haim N, Beny A, et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol. 2001;12(2):227–229. doi: 10.1023/a:1008372228462.
   PubMed Web of Science ®Google Scholar
• Hvistendahl M, Brandt CF, Tribler S, et al. Effect of liraglutide treatment on jejunostomy output in patients with short bowel syndrome: an open-label pilot study. JPEN J Parenter Enteral Nutr. 2018;42(1):112–121. doi: 10.1177/0148607116672265.
   PubMed Web of Science ®Google Scholar
• Kårhus ML, Brønden A, Røder ME, et al. Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide. Gastroenterology. 2019;157(2):569–571. doi: 10.1053/j.gastro.2019.04.002.
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ, Jeppesen PB, Gilroy R, et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol. 2013;11(7):815–823 e1–3. doi: 10.1016/j.cgh.2012.12.029.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kim DY, McKinzie S, et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2003;1(2):111–121. doi: 10.1053/cgh.2003.50019.
   PubMed Web of Science ®Google Scholar
• Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc. 1993;68(7):691–702. doi: 10.1016/s0025-6196(12)60606-5.
   PubMed Web of Science ®Google Scholar